BRIEF published on 03/20/2026 at 15:49, 5 months 22 days ago Guerbet: Publication of the 2025 Universal Registration Document Financial Report Guerbet Medical Imaging Financial Markets Registration Document
BRIEF published on 03/20/2026 at 15:49, 5 months 22 days ago Guerbet : Publication du Document d'enregistrement universel 2025 Rapport Financier Guerbet Imagerie Médicale Marchés Financiers Document D'enregistrement
PRESS RELEASE published on 03/20/2026 at 15:44, 5 months 22 days ago GUERBET : Mise à disposition du Document d’enregistrement universel 2025 Guerbet dépose son Document d’enregistrement universel 2025 à l'AMF. Consultation gratuite en ligne. Prochain RDV : Publication du chiffre d’affaires du 1er trimestre 2026 le 23 avril 2026 Chiffre D’affaires AMF Guerbet Publication Document D’Enregistrement Universel 2025
BRIEF published on 02/20/2026 at 17:50, 6 months 18 days ago Guerbet: Capital update as of January 31, 2026 Voting Rights Capital Actions Guerbet 2026
BRIEF published on 02/20/2026 at 17:50, 6 months 18 days ago Guerbet : Mise à jour sur le capital au 31 janvier 2026 Capital Droits De Vote Actions Guerbet 2026
PRESS RELEASE published on 02/20/2026 at 17:45, 6 months 18 days ago GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2026 Déclaration du nombre de droits de vote et d'actions composant le capital d'une société, conformément à la réglementation en vigueur Droits De Vote Code De Commerce Actions AMF Société
BRIEF published on 01/27/2026 at 18:10, 7 months 14 days ago Approbation européenne pour l'utilisation d'Elucirem™ de Guerbet chez l'enfant dès la naissance Guerbet Commission Européenne Elucirem™ Imagerie Pédiatrique Contraste À Base De Gadolinium
BRIEF published on 01/27/2026 at 18:10, 7 months 14 days ago European Approval for Guerbet's Elucirem™ Use in Children from Birth European Commission Guerbet Elucirem™ Pediatric Imaging Gadolinium-Based Contrast
PRESS RELEASE published on 01/27/2026 at 18:05, 7 months 14 days ago New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission Guerbet's Elucirem (Gadopiclenol) receives European Commission approval for new indication in children from birth, with half-dose GBCA for MRI imaging European Commission Guerbet MRI Imaging Elucirem Gadopiclenol
BRIEF published on 12/19/2025 at 08:50, 8 months 23 days ago Guerbet nomme François Convenant à un poste de direction clé Comité Exécutif Guerbet Innovation Dans Le Secteur De La Santé François Convenant Radiologie Interventionnelle
Published on 09/11/2026 at 15:25, 57 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 1 hour 22 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 1 hour 52 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 13:58, 2 hours 24 minutes ago BlackBerry Radar Advances Asset Intelligence for Transportation
Published on 09/11/2026 at 13:00, 3 hours 22 minutes ago Silver Tiger Intersects 2.1 Metres of 7.72 Kilograms Per Tonne Silver Equivalent in the Caleigh Vein Including 0.53 Metres of 29.62 Kilograms
Published on 09/11/2026 at 16:00, 21 minutes ago Deutsche Postbank Funding Trust III published semi-annual report
Published on 09/11/2026 at 16:00, 21 minutes ago Form 8.3 - IPConcept (Luxemburg) S.A.: SONNTAG Premium
Published on 09/11/2026 at 15:29, 52 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/11/2026 at 07:00, 9 hours 22 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 9 hours 22 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 9 hours 22 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 20 hours 52 minutes ago Availability of the 2026 Interim Financial Report
